Clinical trials
Breast Ductal Carcinoma In Situ clinical trials
Below are recruiting breast ductal carcinoma in situ clinical trials, each written for real people, not researchers. We’re tracking 69 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06677944RecruitingPhase 2
Radiation before surgery for early-stage breast cancer
This trial tests giving radiation to the tumor area before surgery for women with early-stage, hormone-sensitive breast cancer. The idea is to see if giving radiation first can help protect healthy tissue while still being effective.
SeoulAges 45 years+ - NCT05941520RecruitingPhase 2
Acolbifene vs low-dose tamoxifen to prevent breast cancer
This Phase 2 trial compares acolbifene and low-dose tamoxifen to see which better lowers breast cancer risk in premenopausal women at high risk. You would be followed with health visits, blood tests, and a breast tissue sampling procedure.
Duarte, CaliforniaAges 35 years+ - NCT06902311RecruitingPhase 2
Shorter radiation after lumpectomy for early breast cancer
This trial tests a shorter, more intense course of daily radiation therapy (called ultra hypo-fractionation) given after lumpectomy for early-stage breast cancer. The goal is to reduce the number of treatment visits while keeping the same high level of effectiveness and safety.
Chapel Hill, North CarolinaAges 50 years+ - NCT06903468Recruiting
New cavity marking technique for breast cancer surgery and radiation
This trial tests a new way to mark the area where breast cancer is removed during lumpectomy with oncoplastic reconstruction. The goal is to make follow-up radiation more precise and reduce the need for additional surgeries.
Gainesville, FloridaAges 18 years+ - NCT06961955RecruitingPhase 2
Shorter versus longer whole breast radiation for early-stage breast cancer
This trial compares a 5-day course of whole breast radiation plus a boost to the standard 9-day course for people with early-stage breast cancer who have certain risk factors, such as high-grade tumors or younger age. The goal is to see if the shorter treatment is just as safe and effective.
Salt Lake City, UtahAges 18 years+ - NCT06984250Recruiting
Shorter radiation with extra focus on tumor site for breast cancer
This trial tests a shorter course of radiation therapy that includes an extra dose to the tumor site for women with early-stage breast cancer. It aims to make treatment more convenient and effective after breast-conserving surgery.
Taipei, TaiwanAges 20–85 - NCT07095114Recruiting
Disappearing markers for daily breast radiation
This study tests whether small disappearing ink marks can be used to guide daily radiation treatments for breast cancer. It may help make radiation more precise and comfortable.
Detroit, MichiganAges 18 years+ - NCT07214532Recruiting
Guiding CDK4/6 inhibitor use by a blood test in breast cancer
This trial is for women and men with early-stage, hormone-positive, HER2-negative breast cancer. It uses a blood test (Signatera) to detect tiny amounts of cancer DNA and only starts a CDK4/6 inhibitor (ribociclib or abemaciclib) if the test shows cancer DNA is present.
Birmingham, AlabamaAges 18 years+ - NCT07331506Recruiting
Early detection of breast cancer with a blood test
This trial tests a new blood test called Oncoliq to see if it can find breast cancer early. It compares results from people with breast cancer and people without cancer.
Buenos Aires, Buenos AiresAges 40–70 - NCT07339306Recruiting
Fluorescent needle test for breast duct micro-lesions
This trial tests a new glowing needle that helps doctors find and sample tiny abnormal areas in breast ducts during surgery. It aims to make the procedure more precise.
Shenyang, LiaoningAges 18–75 - NCT02918474Recruiting
Decision tool for mastectomy choices in new breast cancer
This study tests a decision-making tool to help people with newly diagnosed breast cancer make choices about removing the other (opposite) breast as a preventive step. It may help you think through risks and options in a clearer, more structured way.
Houston, TexasAges 18 years+ - NCT02620852Recruiting
Wisdom Study: Women’s breast cancer screening decisions
This study looks at how to decide the best breast cancer screening (like mammograms) based on your personal risk. It may help by testing a smarter way to match screening to your risk level.
Birmingham, AlabamaAges 30–74 - NCT02389673Recruiting
Radiation during breast surgery for low-grade DCIS
This trial studies giving radiation during surgery for women with a certain early breast condition called ductal carcinoma in situ (DCIS). It may help lower the chance that the DCIS comes back, especially when combined with breast-conserving surgery.
Guangzhou, GuangdongAges 18–70 - NCT02945579Recruiting
Testing skipping breast surgery or radiation for top responders
This trial studies whether some people with early-stage breast cancer who respond extremely well to hormone/chemo/targeted treatment can safely skip breast surgery and/or radiation. It aims to reduce side effects without increasing cancer risk in carefully selected patients.
Gilbert, ArizonaAges 30 years+ - NCT07478016Recruiting
Studying inflammation and social factors in breast cancer
This study looks at how inflammation and social factors (like stress or support) affect breast cancer patients before they start treatment. You may qualify if you are a woman, newly diagnosed, and have not yet had any cancer treatment.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07507890Recruiting
Nipple-sparing mastectomy through one armpit incision
This trial tests a less invasive surgery for early-stage breast cancer that removes breast tissue through a single small cut in the armpit while keeping the nipple. It may be an option for women with small to medium breasts who are candidates for immediate breast reconstruction.
Candiolo, TurinAges 18 years+ - NCT06843681Enrolling by invitationPhase 2
Trastuzumab and Chemo Before Surgery for HER2-Positive DCIS
This trial tests giving trastuzumab (a targeted drug) plus a chemotherapy drug called a taxane before surgery for women with HER2-positive ductal carcinoma in situ (DCIS), an early form of breast cancer. The goal is to see if this combination can shrink or eliminate the cancer before surgery.
Guangzhou, GuangdongAges 18–70 - NCT07391774RecruitingPhase 3
Hormone therapy with or without chemo for early breast cancer
This trial tests whether skipping chemotherapy and using only hormone therapy with a drug called ribociclib works as well as chemotherapy followed by hormone therapy with ribociclib for certain early breast cancers that have a low risk of coming back.
Jonesboro, ArkansasAges 18 years+ - NCT07613151Recruiting
Lobular breast cancer with low hormone receptors
This study looks at a rare type of breast cancer called invasive lobular carcinoma that has low or no hormone receptors. The goal is to learn more about how this cancer behaves, which may help improve future treatments.
PadovaAges 18 years+ - NCT04797299Recruiting
Testing surgery alone for low-risk ductal carcinoma in situ
This trial studies whether removing the abnormal breast cells with breast-conserving surgery only (without additional treatment) is enough for people with low-risk ductal carcinoma in situ (DCIS). It may help some patients avoid extra treatments if their risk is very low.
Calgary, AlbertaAges 46 years+ - NCT07198724RecruitingPhase 1/Phase 2
A study of elacestrant plus Enhertu for advanced breast cancer
This trial tests a new combination of two targeted drugs (elacestrant and Enhertu) for people with a specific type of advanced breast cancer (HR-positive, HER2-low or ultra-low) that did not respond to standard treatments like CDK4/6 inhibitors. The goal is to see if this combination works better than current options.
Boston, MassachusettsAges 18 years+ - NCT04553770RecruitingPhase 2
Trastuzumab deruxtecan with or without anastrozole for early breast cancer
This Phase 2 study tests whether trastuzumab deruxtecan alone or combined with anastrozole can control early-stage breast cancer that is HER2-low and hormone-receptor positive. It aims to improve outcomes after initial surgical treatment by targeting cancer cells that may have low levels of HER2.
Fullerton, CaliforniaAges 18 years+ - NCT07407920RecruitingPhase 2
Optimizing treatment for early HER2+ and triple-negative breast cancer
This trial aims to see if patients who had a complete response to chemo before surgery can safely stop or reduce their targeted therapy afterward. It includes people with early-stage HER2-positive or triple-negative breast cancer who had no cancer cells left in the tissue removed at surgery (a pathological complete response).
Houston, TexasAges 18 years+ - NCT07432633RecruitingPhase 1/Phase 2
Imaging scan to detect cancer-linked protein in several tumor types
This trial tests a new PET scan tracer that targets a protein found on certain cancer cells. It may help doctors better see and understand tumors in people with colorectal, gastric, pancreatic, lobular breast, or ovarian cancer.
Dallas, TexasAges 18–80
Hear when a new Breast Ductal Carcinoma In Situ trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for breast ductal carcinoma in situ?
- Yes. Clin2 currently lists 69 recruiting breast ductal carcinoma in situ studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast ductal carcinoma in situ trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast ductal carcinoma in situ trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.